4D Lifetec AG was founded in 2014 and is based in Cham, Switzerland.

4D Lifetec develops an artificial intelligence-supported immunological "liquid biopsy" platform for detecting cancer at various stages. The platform operates without the use of genetic databases and provides a simple and cost-effective method with extensive applications. The 4D Lifetest™ developed by 4D Lifetec is initially being developed for the verification of suspected cases of lung, breast, prostate, and colorectal cancer. During the scaling phase, the company aims to develop the test for the verification of cancer in symptomatic patients, to accompany therapies, and later for screening in at-risk patients. An IPO in the USA is planned.

‍